Marta J. Llorca-Cardenosa

Marta J. Llorca-Cardenosa

Auto-generated profile, based on publicly available information

Marta J. Llorca-Cardenosa

The Institute of Cancer Research, London, United Kingdom

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
MLMarta J. Llorca-Cardenosa
Marta J. Llorca-Cardenosa
LALauren I. Aronson
Lauren I. Aronson
DKDragomir B. Krastev
Dragomir B. Krastev
JNJadwiga Nieminuszczy
Jadwiga Nieminuszczy
JAJohn Alexander
John Alexander
ICIrene Chong
Irene Chong
Gastric cancer represents the third leading cause of global cancer mortality and an area of unmet clinical need. Drugs that target the DNA damage response, including ATR inhibitors (ATRi), have been proposed as novel targeted agents in gastric cancer. Here, we sought to evaluate the efficacy of ATRi in preclinical models of gastric cancer and to understand how ATRi resistance might emerge as a means to identify predictors of ATRi response. A positive selection genome-wide CRISPR-Cas9 screen identified candidate regulators of ATRi resistance in gastric cancer. Loss-of-function mutations in either SMG8 or SMG9 caused ATRi resistance by an SMG1-mediated mechanism. Although ATRi still impaired ATR/CHK1 signaling in SMG8/9-defective cells, other characteristic responses to ATRi exposure were not seen, such as changes in ATM/CHK2, γH2AX, phospho-RPA, or 53BP1 status or changes in the proportions of cells in S- or G2–M-phases of the cell cycle. Transcription/replication conflicts (TRC) elicited by ATRi exposure are a likely cause of ATRi sensitivity, and SMG8/9-defective cells exhibited a reduced level of ATRi-induced TRCs, which could contribute to ATRi resistance. These observations suggest ATRi elicits antitumor efficacy in gastric cancer but that drug resistance could emerge via alterations in the SMG8/9/1 pathway. Significance: These findings reveal how cancer cells acquire resistance to ATRi and identify pathways that could be targeted to enhance the overall effectiveness of these inhibitors.

24 November 2025
Verified
Other
Open access
MLMarta J. Llorca-Cardenosa
Marta J. Llorca-Cardenosa
LALauren I. Aronson
Lauren I. Aronson
DKDragomir B. Krastev
Dragomir B. Krastev
JNJadwiga Nieminuszczy
Jadwiga Nieminuszczy
JAJohn Alexander
John Alexander
ICIrene Chong
Irene Chong
SMG8/9 mutation does not reverse the inhibition of ATR/CHK1 signaling but abrogates ATRi-associated cell-cycle effects, RFS, and TRCs. A, SMG8 and SMG9 mutant cells do not show increased pCHK1 (Ser317 and Ser345) or total CHK1 protein expression levels compared with the WT cells after 24 hours of DMSO or 400 nmol/L berzosertib exposure. B, SMG8 (blue) and SMG9 (red) mutant cells are resistant to the CHK1i prexasertib (384-well plate, 5-day assay) compared with the WT cells (black). C–G, Flow cytometry EdU/propidium iodide staining cell-cycle analysis showing the percentage of cells in sub-G1, G1, active S-phase (EdU+ cells), and G2–M cells in the WT cells, two SMG8 mutant and two SMG9 mutant clones after 48 hours of DMSO or 150 nmol/L ATRi exposure. H, SMG8 and SMG9 mutant cells show lower levels of γH2AX and pRPA (S4/S8) protein expression after 48 hours of DMSO or 150 nmol/L berzosertib exposure by Western blot analysis. I, SMG8 (orange) and SMG9 (red) mutant cells show lower levels of γH2AX intensity compared with the WT cells (yellow) after 24 hours of DMSO or 400 or 800 nmol/L of ATRi exposure, despite showing an increase in γH2AX intensity after 3 hours of 3 mmol/L HU. A complete version of the representative image can be found in Supplementary Fig. S4D and S4E. J, SMG8 (orange) and SMG9 (red) mutant cells show lower levels of p53BP1 foci compared with the WT cells (yellow) after 24 hours of DMSO or 400 or 800 nmol/L of ATRi exposure, despite showing an increase in the number of 53BP1 foci after 3 hours of 3 mmol/L HU. A complete version of the representative image can be found in Supplementary Fig. S4D and S4E. K, Western blot analysis showing that SMG1 knockdown rescues levels of γH2AX protein expression in the SMG8 and SMG9 mutant cells after 24 hours of DMSO or 300 mmol/L berzosertib exposure in cells transfected with 1 nmol/L siSMG1 or siCON2, 72 hours before protein extraction. L, SMG1 knockdown rescues the levels of 53BP1 foci in the SMG8 and SMG9 mutant cells after 24 hours of DMSO or 400 or 800 nmol/L of berzosertib exposure after their transfection with 2 μmol/L of siSMG1 or siCON2, 72 hours before protein extraction. HU (3 hours of 3 mmol/L) was used as a positive control. M, SMG8 and SMG9 mutant cells show lower levels of pCHK2 (T68) and pATM (S1981) protein expression by Western blotting in the SMG8 Mut 1 and SMG9 Mut 2 cells after 48 hours exposure to DMSO or 150 nmol/L berzosertib compared with the WT. N, SMG8 and SMG9 mutant cells show increased CIdU track length (a.u.) compared with WT cells in a DNA fiber assay after 24 hours of 300 nmol/L berzosertib or DMSO exposure (20 minutes incubation with 25 μmol/L IdU and 20 minutes incubation with 125 μmol/L CIdU). O, SMG8 and SMG9 mutant cells present decreased forks ratio (a.u.) compared with the WT cells in a DNA fiber assay after 24 hours of 300 nmol/L berzosertib exposure (20 minutes incubation with 25 μmol/L IdU and 20 minutes incubation with 125 μmol/L CIdU). P, SMG8 and SMG9 mutant cells present lower levels of RNAPolII/PCNA PLA foci (measuring TRCs) per cell after 24 hours of 300 nmol/L ATRi, DMSO, or 2 hours of 80 μmol/L of the RNAPII inhibitor DRB exposure. P values were calculated using a one-way ANOVA test). All images are representative of three or more biological replicates. ns, nonsignificant.

24 November 2025
Verified
Other
Open access
MLMarta J. Llorca-Cardenosa
Marta J. Llorca-Cardenosa
LALauren I. Aronson
Lauren I. Aronson
DKDragomir B. Krastev
Dragomir B. Krastev
JNJadwiga Nieminuszczy
Jadwiga Nieminuszczy
JAJohn Alexander
John Alexander
ICIrene Chong
Irene Chong
A proposed model of ATRi resistance caused by SMG8/9 loss of function.

24 November 2025
Verified
Other
Open access
MLMarta J. Llorca-Cardenosa
Marta J. Llorca-Cardenosa
LALauren I. Aronson
Lauren I. Aronson
DKDragomir B. Krastev
Dragomir B. Krastev
JNJadwiga Nieminuszczy
Jadwiga Nieminuszczy
JAJohn Alexander
John Alexander
ICIrene Chong
Irene Chong
Gastric cancer genome-wide CRISPRn screen identifies genetic determinants of ATRi resistance. A, YCC6 and SNU5 gastric tumor cell lines show no ARID1A expression by Western blotting. Other ARID1A-proficient gastric tumor cell lines are represented in this Western blot analysis and HCT116 ARID1A isogenic cell lines were used as positive and negative controls. B and C, Dose–response survival curves (384-well plate, 5-day assay) show that YCC6 and SNU5 (blue) are sensitive to ATRi, compared with the ARID1A-proficient gastric cancer cell lines (black). HCT116 isogenic controls are highlighted in red. D, Schematic illustrating a genome-wide ATRi CRISPR/Cas9 screen using the YCC6 gastric cancer cell line. E, Western blot analysis showing that YCC6 gastric tumor cell line (clone 9) expresses Cas9 upon doxycycline induction after being transduced with an Edit-R Inducible Lentiviral hEF1a-Blast-Cas9 Nuclease vector and selected with blasticidin. F, YCC6 iCas9 cells have a catalytically active Cas9 as shown by flow cytometry. GFP/RFP/Empty represent iCas9 cells transduced with GFP- and RFP-expressing lentiviral constructs. GFP/RFP/gfp-sgRNA represents iCas9 cells that were additionally transduced with a sgRNA-targeting GFP that cleaves the GFP protein thereby decreasing green fluorescence emission. G, Scatter plot illustrating sgRNA z-score for ATRi-resistant cells retrieved at T1 compared with untreated cells retrieved at T0 plotted against the rank calculated from the rank product of z-score and MAGeCK analysis of sgRNA counts. The genes targeted by sgRNA that were most enriched (T1-T0) are highlighted in red at the top right corner of the graph comprising CDC25B, SMG8, SMG9, HUWE1, IRF9, HNRNPF, and CARD10. H, Diagram showing the validation screen workflow. I, Results of the deconvoluted CRISPRn validation screen in 96-well plate format. Each red dot represents an individual sgRNA. P values were calculated by conducting a t test comparing all sgRNAs per gene versus all sgRNAs per the control sgRNA. Dose–response curves, Western blot analysis, and the deconvoluted CRISPRn validation screen in 96-well plate format are representative of three or more biological replicates. ns, nonsignificant.

31 March 2023
Verified
Other
Open access
MLMarta J. Llorca-Cardenosa
Marta J. Llorca-Cardenosa
LALauren I. Aronson
Lauren I. Aronson
DKDragomir B. Krastev
Dragomir B. Krastev
JNJadwiga Nieminuszczy
Jadwiga Nieminuszczy
JAJohn Alexander
John Alexander
ICIrene Chong
Irene Chong
Gastric cancer represents the third leading cause of global cancer mortality and an area of unmet clinical need. Drugs that target the DNA damage response, including ATR inhibitors (ATRi), have been proposed as novel targeted agents in gastric cancer. Here, we sought to evaluate the efficacy of ATRi in preclinical models of gastric cancer and to understand how ATRi resistance might emerge as a means to identify predictors of ATRi response. A positive selection genome-wide CRISPR-Cas9 screen identified candidate regulators of ATRi resistance in gastric cancer. Loss-of-function mutations in either SMG8 or SMG9 caused ATRi resistance by an SMG1-mediated mechanism. Although ATRi still impaired ATR/CHK1 signaling in SMG8/9-defective cells, other characteristic responses to ATRi exposure were not seen, such as changes in ATM/CHK2, γH2AX, phospho-RPA, or 53BP1 status or changes in the proportions of cells in S- or G2–M-phases of the cell cycle. Transcription/replication conflicts (TRC) elicited by ATRi exposure are a likely cause of ATRi sensitivity, and SMG8/9-defective cells exhibited a reduced level of ATRi-induced TRCs, which could contribute to ATRi resistance. These observations suggest ATRi elicits antitumor efficacy in gastric cancer but that drug resistance could emerge via alterations in the SMG8/9/1 pathway.Significance:These findings reveal how cancer cells acquire resistance to ATRi and identify pathways that could be targeted to enhance the overall effectiveness of these inhibitors.

31 March 2023
Verified
Other
Open access
MLMarta J. Llorca-Cardenosa
Marta J. Llorca-Cardenosa
LALauren I. Aronson
Lauren I. Aronson
DKDragomir B. Krastev
Dragomir B. Krastev
JNJadwiga Nieminuszczy
Jadwiga Nieminuszczy
JAJohn Alexander
John Alexander
ICIrene Chong
Irene Chong
Supplementary Table from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance